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Partial “targeted” embolisation of brain
arteriovenous malformations
Abstract Thetreatmentofpialarterio-
venous brain malformations is contro-
versial. Little is yet known about their
natural history, their pathomechanisms
and the efﬁcacy and risks of respective
proposed treatments. It is known that
only complete occlusion of the AVM
can exclude future risk of haemorrhage
and that the rates of curative embolisa-
tion of AVMs with an acceptable
periprocedural risk are around 20 to
50%. As outlined in the present article,
however, partial, targeted embolisation
also plays a role. In acutely ruptured
AVMs where the source of bleeding
can be identiﬁed, targeted embolisation
of this compartment may be able to
secure the AVM prior to deﬁnitive
treatment. In unruptured symptomatic
AVMs targeted treatment may be
employed ifa deﬁned pathomechanism
can be identiﬁed that is related to the
clinical symptoms and that can be
cured with an acceptable risk via an
endovascular approach depending on
the individual AVM angioarchitecture.
This review article gives examples of
pathomechanisms and angioarchitec-
tures that are amenable to this kind of
treatment strategy.
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Introduction
For brain pial arteriovenous malformations, too little is as
of yet known concerning their aetiology, pathophysiology
and natural history to truly and conﬁdently give guidelines
for their treatment. Both advances in diagnostic tools for
pretreatment risk assessment and continuously improved
treatment techniques such as catheterisation and embolisa-
tion materials will presumably change therapeutic risks and
will therefore have an impact on the way we will manage
these vascular malformations. Finally, the skills and
experience of the physician performing the endovascular
treatment have a profound impact on the patient’so u t c o m e ,
which will therefore naturally vary from centre to centre.
In this article, we will nevertheless try to describe our
current approach to pial arteriovenous brain malformations
that is based on an attempt to relate the patient’sc l i n i c a l
ﬁndings to the underlying angioarchitecture in order to
deﬁneangiographictargetsrelatedtothepertinentindividual
pathophysiology [1]. We will, therefore, ﬁrst brieﬂy describe
ac l a s s i ﬁcation of vascular malformations in general, and of
brain AVMs in particular, followed by a description of
angioarchitectural points to consider when treating brain
AVMs. In the last part of this article, we will describe our
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Classiﬁcation of vascular malformations in general
Ac l a s s i ﬁcation of pial brain AVMs that is based upon the
size, the pattern of venous drainage and the eloquence of the
portions of brain adjacent to the AVM [2] is of limited use
when considering an endovascular treatment. First, such
classiﬁcation cannot predict the natural history of a speciﬁc
AVM for an individual patient; second, it does not anticipate
the risk of treating brain AVMs by endovascular techniques;
third, it does not enhance our understanding of this disease.
Concerning the latter, a classiﬁcation that is based upon
the aetiology of vascular malformations may be a more
useful approach to assessing vascular malformative diseases
in general, of which arteriovenous malformations are but a
subgroup [3]. This aetiological classiﬁcation takes into
accountthetarget,thetiming,andthenatureofthetriggering
event [4, 5]. Because arteries and veins are already differ-
entiated early during vasculogenesis, the target of a trigger-
ing event may vary depending on its location along the
vessel tree: Arteries, the arteriovenous junction at the
capillary level, veins, and lymphatic vessels are molecularly
distinct vascular channels and therefore different targets [4].
The second determinant will be the timing when the trigger
hits its target: an early hit during vasculogenesis (such as a
germinal mutation) will affect more cells and will lead to a
metamerically arranged defect, whereas a late hit (such as a
somatic mutation that occurs late during the fetal life or even
postnatally) will have a more focal impact on the vessel [3].
Finally, the nature of the triggering event (intrinsic, i.e.,
genetic vs. extrinsic, i.e., environmental, traumatic or
infectious) will add another level of complexity to this
schematic approach of classifying brain vascular malforma-
tions [6]. Although there is likely to be a continuous
spectrum of vascular diseases rather than clear-cut disease
entities, the scheme that is based on the above-mentioned
assumptions may help to discern vascular malformations
from an aetiological standpoint [7].
The main focus of this article will be on the endovascular
treatment of the shunting lesions. While the above-men-
tioned classiﬁcation may be helpful to broadly categorise
vascular lesions, the most frequently encountered shunting
malformation i.e., the pial brain AVMs, deserve further sub-
classiﬁcation as the presented classiﬁcation is too crude to
predict the natural history of a speciﬁc AVM for an
individual patient and is unable to anticipate the endovas-
cular treatment risk [8].
Classiﬁcation of brain AVMs based on their natural
history
A classiﬁcation that is aimed at predicting the natural history
has todistinguish ﬁrstthoseAVMsthathavebledfromthose
that have not bled, which in most instances will be possible
by the review of the clinical history. In asymptomatic
patients, T2-weighted gradient echo sequences, which are
highly susceptible to depicting signs of old haemorrhage,
may assist in identifying those exceedingly rare cases in
which a subclinical haemorrhage may have occurred [9].
The future risk of bleeding from a brain AVM has been the
subject of many studies. In 1983, Graf et al. published their
results concerning the risk of future haemorrhage, which
were calculated to be 37% in 20 years for unruptured AVMs
and 47% for ruptured AVMs [10]. Crawford et al. found
similar 20-year cumulative risks of haemorrhage (33% for
unruptured and 51% for ruptured AVMs); however, they
added that more advanced age was a major risk factor, with
patients older than 60 years harbouring a risk of rupture of
90% in 9 years [11]. Both studies demonstrated an annual
average risk of haemorrhage of approximately 2%, which
was conﬁrmed in the study in 1988 of Brown et al. who
investigated unruptured AVMs only [12]. He added that the
risk of permanent morbidity and mortality following a
haemorrhage of a brain AVM was 29% and 23%, respec-
tively.Ondraetal.in1990calculatedaslightlyhigherriskof
5%/year for unruptured brain AVMs with a mortality risk of
1% peryear (i.e.,25%for all haemorrhages) and a morbidity
of 2.7%/year (more than 50% for all haemorrhages) [13]. In
a prospective series published by Mast et al. in 1997, the
yearly risk of haemorrhage for previously ruptured brain
AVMs was calculated as 17% per year, whereas in
unruptured AVMs, the risk of haemorrhage was 2% per year
[14]. They found male gender, deep venous drainage and
previous haemorrhages to be the major determinants of
future haemorrhages.
Patho-mechanical classiﬁcation of brain AVMS
While there is, therefore, little discussion about the
necessity of treating pial AVMs that have bled because
of their larger rebleeding risk, pial AVMs that have not
bled have to be further subdivided to select those patients
in whom therapy is indicated, i.e., in whom the therapeutic
risk is lower than the natural history risk. At present a
randomized trial is underway that tries to elucidate the
risks of treatment compared to a conservative manage-
ment. In this trial, which was coined ARUBA (A
Randomized Trial of Unruptured Brain AVMs), subjects
with unruptured AVMs are randomly assigned to either
best possible invasive therapy (endovascular, neurosur-
gical and/or radiation therapy) or medical management
without intervention. Patients will be followed for 5 to a
maximum of 10 years to get a better understanding of the
natural history and the treatment-related risks [15].
In our practice, we try to classify “unruptured” AVMs
according to their pathomechanism (printed subsequently
in italics) in relation to the angioarchitecture and imaging
ﬁndings and thereby decide on the necessity of treatment.
Due to their high-ﬂow shunt, ﬁstulous pial arteriovenous
malformation (Fig. 1), especially when present in child-
2724hood, can lead to psychomotor developmental retardation,
cardiac insufﬁciency and, when present later in life, to
dementia, and therefore merits treatment [16]. Endovas-
cular treatment should be aimed in these cases at reducing
the arteriovenous shunt. Venous congestion (Fig. 2), which
can be due to a high input (ﬁstulous lesions) or a reduced
outﬂow (secondary stenosis of the outﬂow pattern), may
be accompanied by a cognitive decline or epilepsy, and we
would propose treatment in these cases, with the same aim
as stated above [17]. Even if signs of venous congestion
are not present, a long pial course of the draining vein
may indicate that venous drainage restriction is present
over a large area, increasing the risk of venous congestion
and subsequent epilepsy. Conversely, a short vein that
drains almost directly into a dural sinus is unlikely to
interfere with the normal pial drainage. If a patient was to
have epilepsy in this kind of angioarchitecture, MRI
should be scrutinised for signs of perinidal gliosis. While
in the former case (epileptic patient harbouring an AVM
with a long pial draining vein), endovascular treatment is
warranted to reduce the interference with the normal pial
drainage and is likely to reduce the seizure frequency or
severity, in the latter cases (epilepsy following perinidal
gliosis), endovascular therapies are unlikely to change the
seizure frequency or severity, and we would suggest
abstention from an endovascular treatment. Mass effect is
a rare pathomechanism that may result from large venous
ectasias or the nidus proper compressing critical struc-
tures, and may lead to epilepsy, neurological deﬁcits and
even hydrocephalus (Fig. 3)[ 18]. Arterial steal has been
associated with clinical ﬁndings such as migraine and
focal neurological symptoms that most often are transitory
in nature [19]. With the advent of new imaging techniques
such as functional MRI and perfusion weighted MRI, it
has now become possible to visualise, whether or not the
symptoms of a patient can be attributed to a true steal that
can be treated by endovascular means with the aim of
reducing the shunt if the symptoms are disabling.
Angioarchitectural classiﬁcation of brain AVMs
As outlined above, in non-ruptured AVMs the ﬁrst step is
to evaluate whether the speciﬁc symptoms of an individ-
ual patient can be related to the AVM; second, one has to
evaluate whether the pathomechanism responsible for the
symptoms can be treated by endovascular means (as was
also described above). The third step consists in evaluat-
ing the angioarchitecture of the AVM to determine
whether endovascular therapies are suitable for a speciﬁc
brain AVM and whether there are any focal weak points
within the AVM of an asymptomatic patient.
Focal weak points
The basic principle of the concept of “partially targeted
embolisation” of brain AVMs is the hypothesis that speciﬁc
angioarchitectural features of a pial brain AVM can be
regarded as “weak points” that may predispose a patient to
haemorrhage [20–22]. While not proven by randomised
prospective trials, this principle has been used in our
practice for more than 20 years, and we were able to show
an improved outcome on follow-up when compared with
the natural history [23]. These angioarchitectural weak
points are (1) intranidal aneurysms and venous ectasias
[24], and (2) venous stenosis [21]. The ﬁrst to state that a
speciﬁc angioarchitecture present in brain arteriovenous
malformations makes them more prone to future haemor-
rhage were Brown et al. in 1988, who found that the annual
risk of future haemorrhage was 3% in brain AVMs alone
and 7%/year in brain AVMs with associated aneurysms
[12]. Meisel et al. found that among 662 patients with
AVMs, there were 305 patients with associated aneurysms,
and there was a signiﬁcant increase in rebleed episodes in
AVMs harbouring intranidal aneurysms (p<0.002) [24]. In
the Toronto series of 759 brain AVMs, associated
aneurysms were statistically signiﬁcantly (p=0.015) asso-
Fig. 1 Fistulous pial
arteriovenous malformation
with a high-ﬂow shunt.
Although they typically
present in early childhood
when they classically lead to
psychomotor developmental
retardation or cardiac
insufﬁciency, they can also
present later in life; this
typically happens with signs
of venous congestion, i.e.,
epilepsy, or even a cognitive
decline. Multiple shunts of this
type are characteristic of HHT
(hereditary haemorrhagic
telangiectasia)
2725ciated with future bleeding [25]. It may be difﬁcult to
discern intranidal arterial aneurysms from intranidal venous
ectasias (Fig. 4), which is why these two angioarchitectural
speciﬁcities are grouped as one entity in most series.
Venous stenoses, on the other hand, are a separate angio-
graphic weak point and are often seen in ruptured AVMs
(Fig. 5). The nature of the venous stenosis is not completely
understood; most likely, high-ﬂow vessel wall changes or
failure of remodelling (for example, an increased vessel
wall response to the shear stress induced by the arterialisa-
Fig. 3 In rare cases, mass effect of the nidus proper or, as was
present in this case, of the dilated draining vein can lead to
neurological deﬁcits or, as in this case, seizures. Following partial
treatment with embolisation of the large shunt, the size of the
venous pouch regressed, the seizures stopped and the remaining
small nidus was treated with radiosurgery
Fig. 2 Three-dimensional
venous angiogram and venous
phases of an ICA injection
demonstrate the classical
pseudophlebitic aspect of
enlarged and tortuous pial
veins as a sign of longstanding
venous congestion that may
be accompanied by epilepsy,
headaches, cognitive decline and
focal neurological deﬁcits
2726tions) may be put forward as potential reasons. A stenotic
venous outlet will lead to an imbalance of pressure in
various compartments of the AVM, which may induce
subsequent rupture of the AVM. The compartment that is
drained by the stenotic vessel should be scrutinised for
contrast material stagnation and, if endovascular therapy is
contemplated, extreme caution has to be undertaken not to
push the liquid embolic agent towards the already stenosed
vein as this may have catastrophic results. In addition to
these two angioarchitectural risk factors, there are also
other factors that may lead to an increased risk of
haemorrhage. These are: deep venous drainage only,
advanced age and male gender [26].
Angioarchitecture related to endovascular therapies
Before contemplating therapy of an AVM, the angiog-
raphy must be scrutinised for the following points: the
nature and number of the feeding arteries, the presence or
absence of ﬂow-related aneurysms, the number of separate
compartments of the malformation, any arterial or venous
ectasias near to or within the malformation, and the nature
of the venous drainage. On the arterial side, ﬂow-related
aneurysms are typically present at branching points of the
major feeding arteries. They classically resolve following
treatment of the AVM and are due to vascular remodelling
following increased shear stress [27]. Although not a
contraindication for endovascular treatment, they present a
danger to the neurointerventionalist, because ﬂow-directed
catheters are prone to entering the aneurysm rather than
the distal vessels. Concerning the arterial side of the
AVM, both the number and the nature of the feeding
arteries need to be assessed as they determine whether
endovascular approaches will make sense. A large number
of only slightly dilated feeders will make an endovascular
therapy more challenging than those with a single large
feeder [28]. Concerning the nature of the feeding artery,
there are two basic types of feeding arteries. Direct
arterial feeders end in the AVM. Indirect arterial feeders
supply the normal cortex and also supply the AVM “en
passage” via small vessels that arise from the normal
artery. While direct feeders are safe targets for an
endovascular therapy (Fig. 6), en passage feeders may
carry the risk of inadvertent arterial glue migration to
distal healthy vessels (Fig. 7). In this regard, the “security
margin” of the catheter position has to be brieﬂy
discussed. Liquid embolic agents may cause reﬂux at the
end of the injection. Depending on the agent, the micro-
catheter, the injection technique and the skills of the
operator, this reﬂux may be as far as 1 cm proximal to the
tip of the catheter. A safe deposition of liquid embolic
agent is therefore only possible if the catheter tip is distal
enough to be beyond any vessel that supplies normal brain
tissue. In the case of en passage feeders, this may not be
the case, especially if the catheter is only hooked into the
feeding artery and will jump backwards because of the jet
effect when injecting a liquid embolic agent. Concerning
the angioarchitecture of the nidus, intranidal arterial
aneurysms and venous varices that indicate weak points
need to be recognised as well as the number of compart-
ments and their nature (nidal vs. ﬁstulous). Finally, on the
venous side of the AVM, the number of draining veins per
compartment (the more the better for endovascular treat-
ment if venous migration should occur), possible drainage
into the deep venous system (higher risk of haemorrhage,
more difﬁcult surgical treatment) and stenosis, which
restrict venous outﬂow, have to be identiﬁed to fully
determine the risk of a speciﬁc AVM. At the present
time, this information can only be obtained by
Fig. 4 In this patient with an
acutely ruptured AVM, CTA
demonstrates an aneurysm
pointing into the haemorrhagic
cavity as the most likely
source of the bleeding. These
focal points of weakness can
be targeted by embolisation to
secure the AVM in the acute
phase
2727conventional digital subtraction angiography, which in
our practice still precedes any treatment decision in
AVMs.
Concepts of partial targeted embolisation treatment
of brain AVMs
A complete cure of a pial brain AVM by endovascular
means is possible in approximately 20% of all AVMs
irrespective of their angioarchitecture [29–31]. Those
AVMs that are favourable to a complete cure are the
small, single-feeder, single-compartment AVMs that have
a direct feeding artery. As these AVMs are also good
candidates for both radiosurgery and open neurosurgery, a
tailored team approach for each speciﬁc AVM in each
individual patient, also respecting his or her wishes and
the peculiarities of the clinical presentation, will need to
be considered. In most instances, endovascular therapies
will be used to diminish the size of an AVM before
radiotherapy or surgery, to secure focal weak points in the
acute and subacute stage of ruptured AVMs and in
unruptured AVMs where radiosurgery is contemplated,
or to exclude those compartments of an AVM that may be
difﬁcult to reach during surgery. It has to be stressed at
this point that, once therapy of an AVM is contemplated, a
pathway to its complete occlusion has to be agreed upon
by the treatment team, which should include radiosur-
geons, vascular neurosurgeons, neurologists and neuro-
interventionalists. It does not make sense in our opinion to
partially treat an AVM without a strategy on how to
handle a possible residual of the AVM.
Once endovascular therapy is decided upon, we proceed
with a predeﬁned goal, which may mean performing what
Fig. 5 The pathomechansim
of this ruptured AVM is
presumably due to the stenosis
of the major venous outlet
(arrow), which led to
increased pressure within the
nidus proper. If endovascular
therapy is contemplated in
cases like these, extreme
caution has to be taken that no
embolic material penetrates
too far into the venous side
which would lead to further
obstruction of the venous
outﬂow
2728has been coined a partially, targeted embolisation. Such a
rationale is based on the outcome of a series of more than
600 patients with AVMs that were partially embolised and
showed a signiﬁcant decrease in haemorrhagic episodes
when compared with the conservatively treated series
reported in the literature [23]. The yearly haemorrhage
incidence rate of patients before partial treatment was 0.062
[95% CI (0.03, 0.11)]. The observed annual rate after the
start of this regimen was 0.02 [95% CI (0.012, 0.030)] [23].
Given the above-mentioned considerations concerning
focal weak points, we think that these numbers reﬂect the
beneﬁt of selectively excluding speciﬁc weak compart-
ments of an AVM thereby providing early protection while
being scheduled for radiotherapy (whose effects take more
time but whose results concerning complete obliteration are
better). In these instances the goal is to secure the AVM
during its time to complete occlusion. In other instances the
goal may be to preoperatively exclude those compartments
that will be difﬁcult to reach during surgery or to diminish
the size of the AVM before radiosurgery. In the latter
instances, compartments in the periphery of the AVM have
to be targeted, whereas in the former instances, the
neurosurgeon has to point out the target to the neuro-
interventionalist. Because in combined therapies (endovas-
cular + radiotherapy; endovascular + surgery) the relative
risks of each procedure are cumulative, embolisation only
makes sense if a goal is predeﬁned before the therapy. In
most instances, this goal should be reached during a
maximum of two to three endovascular sessions. For most
glomerular pial AVMs, liquid embolic materials are the ﬁrst
choice of treatment. The therapy is done under general
monitoredneuroanaesthesia.We classicallyusea 5F guiding
catheter, which is placed into the distal ICA or VA. A ﬂow-
directed microcatheter is then advanced and directed with a
microguidewireorgentlecontrastmaterialinjectionsintothe
feeding artery and into the nidus proper using roadmap or
ﬂuoroscopy techniques. Here a wedged position of the
catheter tip is sought, paying careful attention that there are
no normal brain-supplying arteries distal to or in close
proximity to the tip of the catheter. After test injections and
preparation of the catheter, the liquid embolic material is
injected into the nidus, while paying careful attention to
avoid venous migration. Depending on the type of embolic
agent and the nidus (ﬁstulous versus nidal), the injection
techniques will vary. To prevent venous migration, tempo-
rary lowering of the blood pressure or compression of
jugular veins may be done. To date, there is an ongoing
debate as to what kind of liquid embolic agent to use.
Personal experience of the authors as well as published data
demonstrates a higher rate of complete obliteration with the
use of Onyx (40–60%), but with a signiﬁcantly increased
treatment-associated risk of permanent morbidity and
Fig. 7 Whereas the feeder type in Fig. 6was of the terminal or “direct”
type, the feeder type of this AVM is of the “indirect” or “en passage”
type. These “en passage” feeders may carry the risk of inadvertent
arterial glue migration to distal healthy vessels and in our opinion speak
strongly to contraindicate an endovascular treatment approach
Fig. 6 Single-feeder AVMs
are easier to embolise with a
higher chance of a complete
cure compared with multi-
feeder AVMs. In this single
compartment AVM, the
microcatheter is brought to an
intranidal position where a
histoacryl deposition was able
to completely occlude the
AVM
2729mortality (8–12%) [32, 33]. Following an uneventful
procedure the patient is awakened and monitored for 24
h, after which discharge of the patient can be proposed.
A proximal occlusion of feeding arteries without
penetration of the embolic material to and just beyond
the site of the shunt will lead to reopening of the nidus
via leptomeningeal collaterals and may induce a pro-
found neoangiogenesis, which should therefore be
avoided, because subsequent endovascular therapies will
not be possible. In addition, the profound neoangio-
genesis will make discrimination between the nidus
proper and normal brain-supplying arteries nearly impos-
sible. In the opinion of the authors, coils and microcoils
are therefore not indicated for nidal type AVMs. It is only
in certain single-hole macroﬁstulae that these embolisa-
tion materials have a place. Likewise, particles, espe-
cially if chosen too large, may lead to an occlusion that is
too proximal with subsequent neoangiogenesis. In addi-
tion, particles do not necessarily result in a stable
occlusion in pial brain AVMs.
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